$JSPR News
Last published 2d ago
- 2d agoJSPRJasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its WarrantsGlobeNewswireREDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development
- 6d agoJSPRTrading halt: Jasper Therapeutics, Inc. (JSPR), News pendingNasdaq Trading HaltsHalted 2026-11-05 19:50:00.000 ET, resumption quote none, resumption trade none.
- 1w agoJSPRJasper Therapeutics Announces 1-for-30 Reverse Stock SplitGlobeNewswireREDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development
- 3w agoJSPRJasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA NephropathyGlobeNewswireInitial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY,
- 1mo agoJSPRJasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsGlobeNewswireREDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development
- 1mo agoJSPRJasper Therapeutics Announces Key Regulatory and Clinical AppointmentsGlobeNewswireLisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) --
- 2mo agoJSPRJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireREDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies
- 2mo agoJSPRJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAcquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising
- 3mo agoJSPRJasper Therapeutics Announces Merger with Kira PharmaceuticalsGlobeNewswireCombined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation
- 5mo agoJSPRJasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueGlobeNewswireREDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 6mo agoJSPRJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 7mo agoJSPRJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy
- 8mo agoJSPRJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 10mo agoJSPRJasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous UrticariaGlobeNewswire67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study
- 10mo agoJSPRJasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical GrowthGlobeNewswireThomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU
- 11mo agoJSPRJasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal InvestigationGlobeNewswireReductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study
- 11mo agoJSPRJasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study InvestigationGlobeNewswireREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody
- 1y agoJSPRJasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoJSPRJasper Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoJSPRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the...
- 1y agoHUMJSPRUNCYVSTSImportant Notice to Long-Term Shareholders of Humana Inc. (NYSE: HUM); Jasper Therapeutics, Inc. (NASDAQ: JSPR); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humana Inc. (NYSE:HUM): Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. (NYSE:HUM). The investigation concerns whether certain
- 1y agoJSPRJSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoJSPRSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the...
- 1y agoJSPRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses in Jasper between
- 1y agoJSPRJasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common WarrantsGlobeNewswireREDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy
- 1y agoJSPRJasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common WarrantsGlobeNewswireREDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy
- 1y agoJSPRJasper Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous UrticariaGlobeNewswire8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at
- 1y agoJSPRJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaGlobeNewswire11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of
- 1y agoJSPRJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressGlobeNewswireREDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingGlobeNewswireREDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy
- 1y agoJSPRJasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswireREDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics to Present at Upcoming March Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingGlobeNewswireREDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous UrticariaGlobeNewswireRapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8
- 1y agoJSPRJasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025GlobeNewswireREDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in AsthmaGlobeNewswireREDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 1y agoJSPRJasper Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 2y agoJSPRJasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireREDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 2y agoJSPRJasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingGlobeNewswireREDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 2y agoJSPRJasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous UrticariaGlobeNewswireREDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
- 2y agoJSPRJasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaGlobeNewswire14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data
- 2y agoJSPRJasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in AsthmaGlobeNewswireREDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy